US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

13.15

-0.1400-1.05%

Volume:72.16K

Turnover:953.38K

Market Cap:726.60M

PE:9.35

High:13.35

Open:13.35

Low:13.15

Close:13.29

52wk High:13.59

52wk Low:11.87

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.27

T/O Rate:0.13%

Dividend:1.42

Dividend Rate:10.77%

EPS(TTM):1.41

ROE:--

ROA:--

PB:0.91

PE(LYR):- -

Loading ...

Overview Company News Filings

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

RA Capital discloses increased PepGen stake at 29%

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

Press Release: Brookfield Real Assets Income Fund Inc. Declares Q4 2025 Distribution Schedule

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.15,"timestamp":1772815269048,"preClose":13.29,"halted":0,"volume":72157,"delay":0,"changeRate":-0.010534236267870489,"floatShares":55245934,"shares":55254696,"eps":1.406,"marketStatus":"Trading","change":-0.14,"latestTime":"03-06 11:41:28 EST","open":13.345,"high":13.345,"low":13.15,"amount":953380.568002,"amplitude":0.014673,"askPrice":13.3,"askSize":200,"bidPrice":12.97,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.406,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772830800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":13.29,"dividendRate":0.107673,"preHourTrading":{"tag":"盘前","latestPrice":13.25,"preClose":13.29,"latestTime":"08:32 EST","volume":800,"amount":10600,"timestamp":1772803936847,"change":-0.04,"changeRate":-0.00301,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":13.29,"preClose":13.29,"latestTime":"16:10 EST","volume":14,"amount":186.04,"timestamp":1772745005085,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.267164},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.267164,"shares":55254696,"dividePrice":1.4159,"high":13.345,"amplitude":0.014673,"preClose":13.29,"low":13.15,"week52Low":11.87,"pbRate":"0.91","week52High":13.59,"institutionHeld":0,"latestPrice":13.15,"eps":1.406,"divideRate":0.107673,"volume":72157,"delay":0,"ttmEps":1.406,"open":13.345,"prevYearClose":12.96,"prevWeekClose":13.46,"prevMonthClose":13.46,"prevQuarterClose":12.96,"fiveDayClose":13.46,"twentyDayClose":13.09,"sixtyDayClose":13.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579930188","title":"Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2579930188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579930188?lang=en_us&edition=fundamental","pubTime":"2025-10-29 23:01","pubTimestamp":1761750060,"startTime":"0","endTime":"0","summary":"Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN","BK4077","BK4178","RA","SLE"],"gpt_icon":0},{"id":"2579790195","title":"Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579790195","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579790195?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:15","pubTimestamp":1761743700,"startTime":"0","endTime":"0","summary":"New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced thera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176538/0/en/Anaptys-Announces-New-Positive-Phase-2b-Trial-Results-for-Rosnilimab-in-Rheumatoid-Arthritis-at-ACR-Late-Breaking-Oral-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR","RA"],"gpt_icon":0},{"id":"2578964388","title":"Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578964388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578964388?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174428/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Data-for-KT-579-a-First-in-Class-Oral-IRF5-Degrader-at-the-American-College-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KT","RA","ACR","BK4139","BK4115","BK4110","LU0541502299.USD","KYMR","IBD","BK4107","AFG","BK4117","LU0541501648.USD"],"gpt_icon":0},{"id":"2576005922","title":"Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576005922","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576005922?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","SLE","CDE","LU1223083913.SGD","BK4077","BK4017","LU1223082519.USD","LU1223082196.USD","BK4107","RA","AFG"],"gpt_icon":0},{"id":"2575874502","title":"Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874502","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874502?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616000,"startTime":"0","endTime":"0","summary":"Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","RA"],"gpt_icon":0},{"id":"2575290639","title":"Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290639","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290639?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-po","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166097/0/en/Telitacicept-Demonstrates-Clinically-Meaningful-and-Statistically-Significant-Impact-on-ESSDAI-Compared-to-Placebo-in-Late-Breaking-China-Phase-3-Results-in-Primary-Sj%C3%B6gren-s-Disea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","BK4110","ACR","RA"],"gpt_icon":0},{"id":"2575863404","title":"Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575863404","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575863404?lang=en_us&edition=fundamental","pubTime":"2025-10-13 21:15","pubTimestamp":1760361300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165570/0/en/Anaptys-Announces-Late-Breaking-Oral-Presentation-of-Complete-Phase-2b-Data-for-Rosnilimab-in-Rheumatoid-Arthritis-at-Upcoming-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4110","RA"],"gpt_icon":0},{"id":"2572309070","title":"RA Capital discloses increased PepGen stake at 29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572309070","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572309070?lang=en_us&edition=fundamental","pubTime":"2025-10-01 09:25","pubTimestamp":1759281905,"startTime":"0","endTime":"0","summary":"In a regulatory filing, RA Capital disclosed it has increased its stake in PepGen (PEPG) by 9.4M shares or $30M. Shares of PepGen are up 3% afterho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ra-capital-discloses-increased-pepgen-stake-at-29-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ra-capital-discloses-increased-pepgen-stake-at-29-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG","RA"],"gpt_icon":0},{"id":"2571835099","title":"Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571835099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571835099?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176300,"startTime":"0","endTime":"0","summary":"Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158108/0/en/Anaptys-Announces-Intent-to-Separate-Biopharma-Operations-from-Substantial-Royalty-Assets-by-Year-end-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","GPP","BK4144","BK4590"],"gpt_icon":0},{"id":"2571350992","title":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350992?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176300,"startTime":"0","endTime":"0","summary":"Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept.  29, 2025  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158104/0/en/ARS-Pharmaceuticals-Secures-Up-to-250-Million-Loan-Facility-with-RA-Capital-Management-and-OMERS-Life-Sciences-to-Accelerate-U-S-Commercialization-of-neffy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","RA"],"gpt_icon":0},{"id":"2571387981","title":"Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387981?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:00","pubTimestamp":1759143600,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  29, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157572/0/en/Vor-Bio-Announces-Late-Breaking-Poster-Presentation-of-Phase-3-Primary-Sj%C3%B6gren-s-Disease-Clinical-Study-at-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4077","RA","LU1223082519.USD","ACR","SLE","BK4110","LU1223083913.SGD","LU1223082196.USD","CDE"],"gpt_icon":0},{"id":"2570830099","title":"Press Release: Brookfield Real Assets Income Fund Inc. Declares Q4 2025 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830099?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:41","pubTimestamp":1758922860,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 26, 2025  -- Brookfield Real Assets Income Fund Inc.   today announced that its Board of Directors  declared the Fund's monthly distributions for October, November and December 2025.Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.Brookfield Real Assets Income Fund Inc. is distributed by Foreside Fund Services, LLC.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2570090978","title":"Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2570090978","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570090978?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:30","pubTimestamp":1758803400,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  25, 2025  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/25/3156282/0/en/Tiziana-to-Advance-TZLS-501-Its-Fully-Human-IL-6R-Monoclonal-Antibody.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU2247934214.USD","BK4532","BK4585","LU2506951875.HKD","LU1430594728.SGD","EA","BK4139","BK4085","BK4588","LU0823417653.USD","LU0950375773.USD","LU0823417737.USD","LU2506952097.USD","BK4577","BK4533","LU2506951958.HKD","LU0006061336.USD","ARDS","LU2506952170.USD","RA"],"gpt_icon":0},{"id":"2569761790","title":"Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2569761790","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569761790?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630600,"startTime":"0","endTime":"0","summary":"MIAMI, FL, Sept.  23, 2025  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometaboli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/23/3154675/11676/en/Veru-Announces-Successful-FDA-Meeting-Providing-Regulatory-Clarity-for-Enobosarm-for-Muscle-Preservation-in-Combination-with-GLP-1-RA-for-Greater-Weight-Loss-in-the-Treatment-of-Ob.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4557","GLP","VERU","RA","BK4590","BK4144","BK4183","BK4007"],"gpt_icon":0},{"id":"2568414601","title":"Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM","url":"https://stock-news.laohu8.com/highlight/detail?id=2568414601","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568414601?lang=en_us&edition=fundamental","pubTime":"2025-09-18 04:15","pubTimestamp":1758140100,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  17, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/17/3152015/0/en/Vor-Bio-Announces-Oral-Presentation-of-48-Week-China-Phase-3-Generalized-Myasthenia-Gravis-Clinical-Study-at-AANEM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}